On May 28, the U.S. Food and Drug Administration (FDA) approved Rapamune (sirolimus), to treat lymphangioleiomyomatosis, a rare, progressive lung disease that primarily affects women of childbearing age. This is the first drug approved to treat the disease. Read more.
